Thomas J Carmody

List of Publications by Year
in descending order

54 papers	5,201 citations	304743 22 h-index	168389 53 g-index
55 all docs	55 docs citations	55 times ranked	6620 citing authors

#	Article	IF	Citations
1	The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 2003, 54, 573-583.	1.3	2,981
2	The Inventory of Depressive Symptomatology (IDS): Clinician (IDS‑C) and Self‑Report (IDS‑SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research, 2000, 9, 45-59.	2.1	328
3	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. Journal of Psychiatric Research, 2016, 78, 11-23.	3.1	216
4	The Montgomery Ãsberg and the Hamilton ratings of depression: A comparison of measures. European Neuropsychopharmacology, 2006, 16, 601-611.	0.7	183
5	Exercise as an Augmentation Treatment for Nonremitted Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, 677-684.	2.2	177
6	Test‑retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. Human Brain Mapping, 2015, 36, 3472-3485.	3.6	136
7	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression. JAMA Psychiatry, 2018, 75, 547.	11.0	125
8	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence. JAMA - Journal of the American Medical Association, 2017, 318, 1876.	7.4	99
9	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. American Journal of Psychiatry, 2015, 172, 881-891.	7.2	87
10	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. American Journal of Psychiatry, 2020, 177, 143-154.	7.2	76
11	Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder. Journal of Clinical Psychiatry, 2017, 78, 1075-1082.	2.2	53
12	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. Biological Psychiatry, 2019, 85, 872-880.	1.3	48
13	Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline. Neuropsychopharmacology, 2001, 25, 131-138.	5.4	45
14	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. Depression and Anxiety, 2016, 33, 56-65.	4.1	43
15	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. American Journal of Psychiatry, 2016, 173, 1196-1204.	7.2	40
16	Making clinicians lives easier: Guidance on use of the QIDS self-report in place of the MADRS. Journal of Affective Disorders, 2006, 95, 115-118.	4.1	33
17	Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study. Journal of Psychiatric Research, 2019, 113, 165-171.	3.1	33
18	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. American Journal of Nephrology, 2019, 50, 37-47.	3.1	31

#	Article	IF	Citations
19	A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder. American Journal of Psychiatry, 2015, 172, 1014-1021.	7.2	30
20	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. Magnetic Resonance Imaging, 2018, 45, 26-33.	1.8	28
21	Discovery and replication of cerebral bloodÂflow differences in major depressive disorder. Molecular Psychiatry, 2020, 25, 1500-1510.	7.9	28
22	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. PLoS ONE, 2016, 11, e0167901.	2.5	26
23	Decision-making processes as predictors of relapse and subsequent use in stimulant-dependent patients. American Journal of Drug and Alcohol Abuse, 2016, 42, 88-97.	2.1	23
24	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. Biological Psychiatry, 2020, 88, 657-667.	1.3	23
25	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 6, 22-30.	1.1	22
26	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. Depression and Anxiety, 2020, 37, 771-783.	4.1	22
27	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). Journal of Psychiatric Research, 2020, 122, 22-32.	3.1	21
28	A Systematic Review and Meta-Analysis of Depression and Protein–Energy Wasting in Kidney Disease. Kidney International Reports, 2020, 5, 318-330.	0.8	20
29	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. EClinicalMedicine, 2019, 10, 32-41.	7.1	19
30	Brain imaging demonstrates a reduced neural impact of eating in obesity. Obesity, 2016, 24, 829-836.	3.0	17
31	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. Journal of Affective Disorders, 2019, 245, 1070-1078.	4.1	17
32	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. Journal of Clinical Psychiatry, 2016, 77, 1036-1042.	2.2	15
33	Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. Journal of Affective Disorders, 2016, 200, 156-158.	4.1	15
34	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. Journal of Psychiatric Research, 2018, 102, 65-71.	3.1	14
35	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. Journal of Psychopharmacology, 2019, 33, 185-193.	4.0	14
36	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2020, 126, 19-25.	3.1	14

#	ARTICLE	IF	CITATIONS
37	Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. Molecular Neuropsychiatry, 2018, 4, 7-19.	2.9	12
38	Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis. General Hospital Psychiatry, 2016, 42, 60-66.	2.4	9
39	A complier average causal effect analysis of the Stimulant Reduction Intervention using dosed exercise study. Contemporary Clinical Trials Communications, 2018, 10, 1-8.	1.1	9
40	The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors. BMC Cancer, 2018, 18, 744.	2.6	7
41	The Concise Health Risk Tracking Self–Report (CHRT–SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. Depression and Anxiety, 2019, 36, 313-320.	4.1	7
42	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. Journal of Personalized Medicine, 2022, 12, 412.	2.5	7
43	Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression. American Journal of Kidney Diseases, 2020, 75, 457-460.	1.9	6
44	Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. Psychological Medicine, 2022, 52, 2441-2449.	4.5	6
45	The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials. Translational Psychiatry, 2021, 11, 531.	4.8	6
46	Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial. Personalized Medicine in Psychiatry, 2018, 9-10, 1-7.	0.1	5
47	Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR). Journal of Clinical Psychiatry, 2018, 79, 41-47.	2.2	5
48	Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders. American Journal on Addictions, 2016, 25, 215-220.	1.4	4
49	Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD. Kidney360, 2020, 1, 436-446.	2.1	4
50	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. Journal of Psychiatric Research, 2022, 149, 243-251.	3.1	4
51	Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study. Journal of Affective Disorders, 2021, 295, 1066-1071.	4.1	3
52	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C5) and Self-Report (VQIDS-SR5) Versions of the Very Quick Inventory of Depressive Symptoms. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 289-302.	2.2	3
53	Long-term results of interstitial implant in locally advanced cervical cancer:A retrospective study of 50 cases. Radiation Oncology Investigations, 1996, 4, 33-40.	0.9	2
54	Moderators of treatment response to exercise in participants with stimulant use disorder: Exploratory results from the Stimulant Reduction using Dosed Exercise (STRIDE)CTN-0037 study. Mental Health and Physical Activity, 2021, 21, 100421.	1.8	0